Filtered By:
Source: Atherosclerosis
Drug: Aspirin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 152 results found since Jan 2013.
A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial
Lancet Glob Health. 2023 Oct;11(10):e1619-e1628. doi: 10.1016/S2214-109X(23)00347-9.ABSTRACTBACKGROUND: A cardiovascular polypill containing generic drugs might facilitate sustained implementation of and adherence to evidence-based treatments, especially in resource-limited settings. However, the impact of a cardiovascular polypill in mitigating atherosclerotic risk among stroke survivors has not been assessed. We aimed to compare a polypill regimen with usual care on carotid intima-media thickness (CIMT) regression after ischaemic stroke.METHODS: In SMAART, a phase 2 parallel, open-label, assessor-masked, randomised clini...
Source: Atherosclerosis - September 21, 2023 Category: Cardiology Authors: Fred Stephen Sarfo Jenifer Voeks Sheila Adamu Benedict Apaw Agyei Manolo Agbenorku Nyantakyi Adu-Darko Mercy Adomah Oteng Vida Obese Rexford Adu Gyamfi Nathaniel Adusei Mensah Raelle Tagge Michael Ampofo Samuel Amoabeng Kontoh Samuel Blay Nguah Bruce Ovbi Source Type: research
Transient left bundle branch block associated with very high coronary artery calcium: a case report
We present a case of very high CAC in a 64-year-old woman with hypertension, type 2 diabetes, and hyperlipidemia presenting with dyspnea. Initial electrocardiogram (ECG) demonstrated normal conduction with a heart rate of 76 beats/min, but new T-wave inversions in V1-V4 and a high-sensitivity troponin-I (hsTnI) value of 6 ng/L (normal < 6 ng/L). Repeat ECG in the emergency department showed normal sinus rhythm (heart rate of 80 beats/min); however, it subsequently demonstrated a left bundle branch block (LBBB) with a repeat hsTnI of 7 ng/L. Stress testing with pharmacologic single-photon emission computerized tomography...
Source: Atherosclerosis - September 19, 2023 Category: Cardiology Authors: Alexander C Razavi Sindhu Prabakaran Mariem Sawan Lakshmi Tummala Ifeoma Onuorah Sagar B Amin Marly van Assen Carlo N De Cecco Arshed A Quyyumi Seamus P Whelton Laurence S Sperling Francois G Rollin Source Type: research
Atherosclerosis as a Risk Factor for IBD: A Population-Based Case-Control Study
CONCLUSIONS: A history of an atherosclerotic-related condition is associated with increased odds of developing IBD, particularly among older adults. Future studies should investigate whether drugs targeting atherosclerotic-related inflammation may prevent IBD in higher-risk individuals.PMID:37721310 | DOI:10.14309/ajg.0000000000002502
Source: Atherosclerosis - September 18, 2023 Category: Cardiology Authors: Adam S Faye Jordan Axelrad Jiangwei Sun Jonas Halfvarson Jonas S öderling Ola Ol én Jonas F Ludvigsson Source Type: research
Risk factors and a prediction model for unruptured intracranial aneurysms in patients with ischemic stroke using carotid intima-media thickness and systemic atherosclerosis
CONCLUSION: The findings revealed that the risk factors for UIA in patients with IS included aspirin use, elevated CRP level, and smaller carotid IMT, and the predictive value of the prediction model was relatively better.PMID:37706007 | PMC:PMC10495834 | DOI:10.3389/fneur.2023.1227673
Source: Atherosclerosis - September 14, 2023 Category: Cardiology Authors: Gaiming Gao Dezhi Kang Jinning Zhang Zhixian Jiang Xueyang He Yanyu Wu Source Type: research
Early Computed Tomography Coronary Angiography and Preventative Treatment in Patients with Suspected Acute Coronary Syndrome A secondary analysis of the RAPID-CTCA trial
CONCLUSIONS: Prescription patterns of preventative treatment varied during index hospitalisation in patients with suspected acute coronary syndrome. Early CTCA facilitated targeted individualisation of these therapies based on the extent of coronary artery disease.PMID:37709109 | DOI:10.1016/j.ahj.2023.09.003
Source: Atherosclerosis - September 14, 2023 Category: Cardiology Authors: Kang-Ling Wang Mohammed N Meah Anda Bularga Katherine Oatey Rachel O'Brien Jason E Smith Nick Curzen Attila Kardos Liza Keating Dirk Felmeden Robert F Storey Steve Goodacre Carl Roobottom David E Newby Alasdair J Gray RAPID-CTCA Investigators Source Type: research
AEE alleviates ox-LDL-induced lipid accumulation and inflammation in macrophages
Biomed Pharmacother. 2023 Sep 12;167:115486. doi: 10.1016/j.biopha.2023.115486. Online ahead of print.ABSTRACTAtherosclerosis is a chronic immune inflammatory disease. Aspirin eugenol ester (AEE) is a novel safe and non-toxic compound with many pharmacological effects such as anti-inflammatory, anti-hyperlipidemic and anti-thrombotic action. In order to investigate the effect of AEE on the inhibition of aortic lipid plaque formation and macrophage-derived foam cell formation induced by oxidized low density lipoprotein (ox-LDL), in vivo atherosclerosis model by feeding ApoE-/- mice with a high-fat diet and foam cells format...
Source: Atherosclerosis - September 14, 2023 Category: Cardiology Authors: Ya-Xian Liu Xi-Wang Liu Ya-Jun Yang Shi-Hong Li Li-Xia Bai Wen-Bo Ge Xiao Xu Cun Li Jian-Yong Li Zhe Qin Source Type: research
Plasma protein signatures for high on-treatment platelet reactivity to aspirin and clopidogrel in peripheral artery disease
CONCLUSIONS: A plasma protein signature, including eight targets involved in proatherogenic dysfunction of blood cell-vasculature interaction, coagulation and cell death, is associated with HTPR (aspirin and/or clopidogrel) in PAD. This may serve as important systems-based determinants of poor platelet responsiveness to aspirin and/or clopidogrel in PAD and other cardiovascular diseases and may contribute to identify novel treatment strategies.PMID:37708596 | DOI:10.1016/j.thromres.2023.08.017
Source: Atherosclerosis - September 14, 2023 Category: Cardiology Authors: G Baidildinova A Pallares Robles V Ten Cate B M M Kremers S Heitmeier H Ten Cate B M E Mees H M H Spronk P S Wild A J Ten Cate-Hoek K Jurk Source Type: research
Aspirin for primary prevention in patients with high cardiovascular risk: insights from CORE-Thailand registry
Sci Rep. 2023 Sep 5;13(1):14646. doi: 10.1038/s41598-023-41864-1.ABSTRACTAspirin may be considered for primary prevention in non-elderly patients with high cardiovascular risk. However, contemporary management aimed at aggressive cardiovascular risk factor control may alter benefit-risk ratio of aspirin. Therefore, we aimed to examine the effect of aspirin for primary prevention on the long-term MACEs in a large cohort registry. Cohort Of patients with high Risk for cardiovascular Events (CORE-Thailand) registry is a prospective, multicenter, observational, longitudinal study of Thai patients with high atherosclerotic risk...
Source: Atherosclerosis - September 5, 2023 Category: Cardiology Authors: Wanwarang Wongcharoen Nichanan Osataphan Narawudt Prasertwitayakij Pannipa Suwannasom Swangjit Suraamornkul Wattana Wongtheptian Siriluck Gunaparn Wachiranun Sirikul Arintaya Phrommintikul Source Type: research
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes
Life (Basel). 2023 Jul 31;13(8):1669. doi: 10.3390/life13081669.ABSTRACTEvidence suggests that inflammation plays an important role in atherosclerosis and the consequent clinical presentation, including stable coronary artery disease (CAD) and acute coronary syndromes (ACS). The most essential elements are cytokines, proteins with hormone-like properties that are produced by the immune cells, endothelial cells, platelets, fibroblasts, and some stromal cells. Interleukins (IL-1β and IL-6), chemokines, interferon-γ (IFN-γ), and tumor necrosis factor-alpha (TNF-α) are the cytokines commonly associated with endothelial dys...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Yannis Dimitroglou Constantina Aggeli Panagiotis Theofilis Panagiotis Tsioufis Evangelos Oikonomou Christos Chasikidis Konstantinos Tsioufis Dimitris Tousoulis Source Type: research
Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
J Clin Med. 2023 Aug 14;12(16):5284. doi: 10.3390/jcm12165284.ABSTRACTDespite evidence-based therapies, patients presenting with atherosclerosis involving more than one vascular bed, such as those with peripheral artery disease (PAD) and concomitant coronary artery disease (CAD), constitute a particularly vulnerable group characterized by enhanced residual long-term risk for major adverse cardiac events (MACE), as well as major adverse limb events (MALE). The latter are progressively emerging as a difficult outcome to target, being correlated with increased mortality. Antithrombotic therapy is the mainstay of secondary pre...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Giulia Magnani Andrea Denegri Filippo Luca Gurgoglione Federico Barocelli Elia Indrigo Davide Catellani Gianluca Signoretta Alberto Bettella Domenico Tuttolomondo Emilia Solinas Francesco Nicolini Giampaolo Niccoli Diego Ardissino Source Type: research
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes
Life (Basel). 2023 Jul 31;13(8):1669. doi: 10.3390/life13081669.ABSTRACTEvidence suggests that inflammation plays an important role in atherosclerosis and the consequent clinical presentation, including stable coronary artery disease (CAD) and acute coronary syndromes (ACS). The most essential elements are cytokines, proteins with hormone-like properties that are produced by the immune cells, endothelial cells, platelets, fibroblasts, and some stromal cells. Interleukins (IL-1β and IL-6), chemokines, interferon-γ (IFN-γ), and tumor necrosis factor-alpha (TNF-α) are the cytokines commonly associated with endothelial dys...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Yannis Dimitroglou Constantina Aggeli Panagiotis Theofilis Panagiotis Tsioufis Evangelos Oikonomou Christos Chasikidis Konstantinos Tsioufis Dimitris Tousoulis Source Type: research
Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
J Clin Med. 2023 Aug 14;12(16):5284. doi: 10.3390/jcm12165284.ABSTRACTDespite evidence-based therapies, patients presenting with atherosclerosis involving more than one vascular bed, such as those with peripheral artery disease (PAD) and concomitant coronary artery disease (CAD), constitute a particularly vulnerable group characterized by enhanced residual long-term risk for major adverse cardiac events (MACE), as well as major adverse limb events (MALE). The latter are progressively emerging as a difficult outcome to target, being correlated with increased mortality. Antithrombotic therapy is the mainstay of secondary pre...
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Giulia Magnani Andrea Denegri Filippo Luca Gurgoglione Federico Barocelli Elia Indrigo Davide Catellani Gianluca Signoretta Alberto Bettella Domenico Tuttolomondo Emilia Solinas Francesco Nicolini Giampaolo Niccoli Diego Ardissino Source Type: research
